Discover Where Theranostics Is Making a Difference
While its role varies depending on the cancer type, theranostics combines advanced diagnostic imaging with targeted radionuclide therapies to support more personalised approaches to patient care.
This page provides an overview of where theranostics is currently being used, where research is ongoing and where you can find trusted information about specific cancers.
If you have questions about your individual circumstances, treatment options or eligibility for theranostic approaches, please speak with your healthcare team.
Prostate Cancer
Prostate cancer is currently one of the most established areas for theranostics.
Advances in Prostate-Specific Membrane Antigen (PSMA) imaging and radioligand therapy have helped improve the identification and management of prostate cancer for selected patients.
Treatments
Theranostic approaches may involve:
-
PSMA PET imaging
-
PSMA-targeted radioligand therapies
-
Monitoring of treatment response through molecular imaging
Treatment suitability depends on individual patient circumstances and specialist assessment.
Research
Research continues to investigate:
-
Earlier use of PSMA-targeted therapies
-
Combination treatment approaches
-
New imaging and therapeutic targets
Patient Guide
Patients with prostate cancer who are interested in theranostics should discuss available imaging and treatment options with their healthcare team.
Read More >>
Learn More
Cancer Council Australia:
https://www.cancer.org.au/cancer-information/types-of-cancer/prostate-cancer
Prostate Cancer Foundation of Australia:
https://www.pcfa.org.au
Neuroendocrine Tumours (NETs)
Theranostics has become an important treatment pathway for selected patients with neuroendocrine tumours.
Imaging and treatment approaches targeting somatostatin receptors are widely used in clinical practice.
Treatments
Theranostic approaches may include:
-
Somatostatin receptor imaging
-
Peptide Receptor Radionuclide Therapy (PRRT)
Research
Researchers continue to explore:
-
Earlier intervention strategies
-
Improved targeting approaches
-
Expanded applications across NET subtypes
Patient Guide
Patients diagnosed with neuroendocrine tumours may wish to discuss PRRT and other treatment options with their treating specialist.
Learn More
Cancer Council Australia:
https://www.cancer.org.au/cancer-information/types-of-cancer/neuroendocrine-tumours
NeuroEndocrine Cancer Australia:
https://neuroendocrine.org.au
Thyroid Cancer
Theranostic principles have been used in thyroid cancer management for many years through radioactive iodine imaging and treatment approaches.
This represents one of the earliest examples of theranostics in clinical practice.
Treatments
Depending on the individual case, treatment may include:
-
Radioiodine imaging
-
Radioiodine therapy
-
Ongoing monitoring and follow-up
Research
Research continues to investigate:
-
Novel targets
-
Advanced imaging techniques
-
Treatment options for more challenging disease settings
Patient Guide
Treatment approaches vary significantly between different types of thyroid cancer and should always be discussed with a specialist healthcare team.
Learn More
Cancer Council Australia:
https://www.cancer.org.au/cancer-information/types-of-cancer/thyroid-cancer
Australian Thyroid Foundation:
https://www.thyroidfoundation.org.au
Non-Melanoma Skin Cancer
Theranostic approaches are increasingly being explored and utilised in the management of selected non-melanoma skin cancers.
Innovations in imaging, targeted therapies and radionuclide treatments continue to expand treatment possibilities.
Treatments
Appropriate treatment options vary depending on:
-
Cancer type
-
Disease stage
-
Location
-
Patient circumstances
Research
Research is ongoing into:
-
Novel radionuclide therapies
-
Personalised treatment approaches
-
Improved patient outcomes
Patient Guide
Patients should discuss available treatment options with their dermatologist, radiation oncologist or other treating specialist.
Learn More
Cancer Council Australia:
https://www.cancer.org.au/cancer-information/types-of-cancer/skin-cance
Emerging Areas of Research
While some approaches remain investigational, ongoing clinical studies continue to expand understanding of where theranostics may contribute to future patient care.
Research
Researchers are currently investigating the potential role of theranostics across a growing range of cancers, including:
-
Breast cancer
-
Lung cancer
-
Brain cancer
-
Ovarian cancer
-
Pancreatic cancer
-
Colorectal cancer
-
Melanoma
-
Multiple myeloma
Frequently asked questions
Can theranostics be used for every cancer type?
Is theranostics only used in cancer?
How do I know if my cancer may be suitable for theranostics?
Continue Exploring
Discover how theranostics is changing the future of personalised healthcare.
What is Theranostics >>
Find practical information and support for every stage of your journey.
Patient Support >>
Explore clinical insights, research developments and collaboration opportunities shaping the future of theranostics.
Visit Professionals >>
Frequently Asked Questions
Explore answers to some of the most common questions about theranostics, precision medicine and targeted cancer care.
Discover Now >>
Stay Connected
Join our community to receive educational resources, industry updates, event invitations and the latest developments in theranostics.
Join Our Community >>
GET IN TOUCH
Let’s Collaborate
Reach out to us to explore opportunities for collaboration and learn more about our initiatives in advancing Theranostic treatment accessibility.
Medical Disclaimer
The information provided on this website is intended for educational purposes only and should not be considered medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals who can consider individual circumstances and clinical needs.
Support Us
Make A Donation
Sponsor Enquiry
Contact Us
Follow Us
Quick Links
Theranostics Hub
Cancer Types
Patient Information
HCP Information
News & Events
Oncothera Advocacy is a Registered Charity with the Australian Charities and Not–for–profit Commission.